

| Package | Price per Dose | Price | |
|---|---|---|---|
| 360 pills | £1.23 | £441.88 Free shipping | |
| 180 pills | £1.31 | £235.13 Free shipping | |
| 120 pills | £1.36 | £163.57 Free shipping | |
| 90 pills | £1.47 | £131.76 | |
| 60 pills | £1.57 | £94.27 | |
| 30 pills | £1.73 | £52.24 | |
| 360 pills | £1.34 | £482.77 Free shipping | |
| 180 pills | £1.42 | £255.58 Free shipping | |
| 120 pills | £1.49 | £178.33 Free shipping | |
| 90 pills | £1.60 | £144.26 | |
| 60 pills | £1.70 | £102.23 | |
| 30 pills | £1.89 | £56.79 | |
| 10 pills | £2.27 | £22.71 | |
| 360 pills | £2.00 | £720.19 Free shipping | |
| 180 pills | £2.12 | £382.81 Free shipping | |
| 120 pills | £2.23 | £266.94 Free shipping | |
| 90 pills | £2.39 | £214.69 Free shipping | |
| 60 pills | £2.54 | £152.21 Free shipping | |
| 30 pills | £2.81 | £84.05 | |
| 10 pills | £3.98 | £39.75 |
Leukotrienes are inflammatory molecules released during allergic reactions and asthma flares. They contribute to airway swelling, mucus production, and bronchial constriction, which can worsen coughing, wheeze, and nasal congestion. This biological pathway helps explain why medicines that block leukotrienes can lessen symptoms for some people.
Montelukast belongs to a class of medications called leukotriene receptor antagonists. By blocking the action of leukotrienes on their receptors in the airways and nasal passages, montelukast can reduce inflammation and relieve symptoms of allergic rhinitis and asthma. It is often used as an add‑on therapy when symptoms persist despite other treatments, or as an alternative for people who prefer a once‑daily tablet.
For many patients, montelukast offers a convenient option because it is taken by mouth and does not rely on inhalers or nasal sprays alone. It does not provide immediate relief during an acute asthma attack or severe allergic reaction, so it is not a substitute for rescue medications. Check with a clinician if you are unsure how montelukast fits into your overall plan.
The medication is widely prescribed in the United Kingdom as part of a broader strategy to control chronic symptoms and reduce the frequency of wheeze, nasal symptoms, and related discomfort. While it can help with allergen‑triggered symptoms, it is not a universal remedy and response can vary between individuals. If you have a history of admissions for asthma or complex allergies, your healthcare team may monitor montelukast use more closely.
As with any long‑term therapy, ongoing assessment matters. Your clinician may adjust the treatment plan based on how well symptoms are controlled, side effects, and interactions with other medicines. If you notice new or concerning symptoms after starting montelukast, seek medical advice promptly to determine the best course of action.
Singulair is the brand name for montelukast. It is approved for use in several chronic airway and allergic conditions, including asthma and allergic rhinitis. In the UK, montelukast is prescribed for specific scenarios, often as an add‑on option when first‑line treatments do not fully manage symptoms. Your GP or specialist will decide if it is appropriate for you.
In asthma, montelukast is used as a preventive medication rather than a reliever. It can help reduce the frequency of asthma symptoms and the need for short‑acting bronchodilators in some patients, particularly those whose symptoms are triggered by allergies or exercise. It may be chosen for individuals who cannot tolerate inhaled corticosteroids or who require an additional tool alongside inhaled therapies.
For allergic rhinitis, montelukast helps with nasal congestion, sneezing, runny nose, and itching. It can be a useful option for people who prefer an oral daily tablet or who experience simultaneous asthma and allergic rhinitis symptoms. It is not a cure for allergies, and avoidance of triggers remains important.
Montelukast has also been used in certain rare settings where inflammation affects the airways. In these scenarios, clinicians weigh potential benefits against possible risks, as with any long‑term therapy. If you are unsure why montelukast is being considered for you, ask your clinician to explain how it may help in your specific condition.
As with all medicines, montelukast works differently from person to person. Some patients report meaningful improvement in daytime symptoms and nighttime sleep, while others may notice only modest changes. A healthcare professional can help interpret your response and decide whether to continue, adjust, or discontinue treatment.
Montelukast is not suitable for everyone. People with known hypersensitivity to montelukast or any component of the tablet should avoid use. If you have had an allergic reaction to montelukast or any leukotriene receptor antagonist in the past, tell your clinician before starting the medicine.
Severe liver disease calls for careful consideration, because the body's processing of montelukast can be affected. If you have significant liver impairment, your doctor may adjust the plan or choose an alternative treatment. Do not take montelukast if you have an active liver condition that your clinician has discussed with you as contraindicated.
Montelukast may interact with other medicines or conditions. A clinician will assess for potential interactions that could worsen safety or reduce effectiveness. If you are taking medicines that affect the liver, or if you have a complex medical history, you should seek tailored guidance before starting montelukast.
In rare cases, montelukast can be associated with mood changes or neuropsychiatric effects. If you have a history of mental health disorders, or if you notice new or worsening mood symptoms after starting treatment, contact a healthcare professional promptly. Seek urgent medical help if you develop severe mood changes, agitation, thoughts of self‑harm, or uncontrolled aggression.
Children and adolescents should have their response and any side effects monitored closely. The safety profile is assessed with age and developmental considerations in mind. If your child has a history of behavioural issues, discuss this with a clinician before initiating montelukast therapy.
Montelukast requires careful monitoring, especially during the first weeks of treatment and when changing dosages. An assessment of symptom control, sleep quality, and any new side effects helps determine whether montelukast remains appropriate. Do not stop a treatment plan abruptly without professional guidance.
Neuropsychiatric symptoms have been reported in some people taking montelukast. While most occurrences are mild and transient, there have been rare reports of mood disorders, anxiety, and agitation. If these symptoms appear or worsen, contact a clinician promptly. In severe cases, seek urgent medical help.
Clinicians may check liver function in certain patients or when montelukast is used alongside other medicines with potential liver effects. If you notice unusual fatigue, dark urine, pale stools, or yellowing of the skin or eyes, report this to a healthcare professional. Do not assume these signs are related to montelukast without medical confirmation.
Allergic reactions to montelukast‑containing products can occur, though they are uncommon. Symptoms to watch for include rash, itching, swelling of the face or tongue, and trouble breathing. If any signs of serious allergy appear, seek urgent medical help.
Children and adults should be advised to continue allergen and trigger avoidance strategies where possible. Montelukast is a tool within a broader plan for asthma and allergic rhinitis, not a standalone cure. If symptoms persist despite montelukast, a clinician may adjust other therapies or explore alternative options.
Headache, abdominal pain, and diarrhoea are among the more frequently reported experiences when starting montelukast. These effects are usually mild and tend to resolve with continued treatment or after dose adjustments. If they persist or worry you, speak with a pharmacist or clinician for guidance.
Nausea or an upset stomach can occur, particularly in the first weeks of therapy. Having meals or a light snack with the tablet may help some people. If symptoms are persistent, a clinician can assess whether montelukast remains the best option for you.
Changes in behaviour or mood have been noted in some people, including restlessness or sleep disturbances. If these occur and affect daily life, report them to your healthcare professional. They may recommend monitoring more closely or trying a different approach.
Back pain or generalised tiredness can occur in a minority of patients. These complaints are typically non‑specific and do not necessarily indicate a problem with montelukast. Ongoing symptom checks are advised if such effects arise.
Rash, itching, or swelling around the lips or eyes can signal an allergic reaction. If any of these develop, particularly with breathing difficulties, seek urgent medical attention. Even if the reaction seems mild at first, it should be evaluated by a clinician.
Swelling of the face, tongue, or throat may indicate a serious allergic reaction. This requires immediate medical assessment. Do not wait to see if symptoms improve on their own.
In very rare cases, montelukast has been linked to liver enzyme changes. If you notice persistent fatigue, dark urine, or yellowing of the skin, contact a clinician promptly for evaluation. Do not assume these signs are due to the medication without medical advice.
Seizure activity has been reported in isolated instances during montelukast therapy. If you have a history of seizures or development of seizure‑like events, discuss this with your clinician before starting montelukast and report any new events promptly.
If you miss a dose, take it as soon as you remember, unless it is almost time for the next one. Do not double up the dose to make up for a missed one. If you are unsure what to do, contact your pharmacist or clinician for guidance.
If you decide to stop montelukast, do so only after discussing with a clinician. Stopping abruptly may lead to a return or worsening of symptoms. Your treatment plan may be adjusted to maintain control with other therapies where needed.
Monitor symptom patterns after any change in therapy. If symptoms worsen or you experience new side effects, arrange a review with your healthcare professional. They can help determine the most appropriate next steps.
Children should be observed for behavioural or mood changes, as these can affect sleep, school performance, or social interactions. Report any concerns to a clinician promptly for guidance on care and safety.
Several medicines can interact with montelukast by altering how it is processed in the body. A clinician will review current therapies to identify potential interactions and minimise risk. Always share a complete list of medicines, including any antacids or antifungal agents you may take.
In some cases, montelukast and other asthma or allergy medicines may have combined effects. Your clinician might adjust the treatment plan to balance benefits and safety. Do not modify dosages without professional guidance.
If you use medicines for seizures or mental health conditions, discuss montelukast with your prescriber. Some central nervous system‑acting drugs can interact in ways that require monitoring or alternative strategies.
Always tell your pharmacist about any new prescriptions you receive. They can help verify whether montelukast remains compatible with your broader regimen before you fill the new prescription.
Over‑the‑counter anti‑inflammatory medicines or herbal products can interact indirectly with montelukast, or alter the way your body handles it. For example, certain supplements may affect liver function or interact with other medicines you are taking. When in doubt, discuss any supplement use with a clinician or pharmacist.
Fish oil, vitamin E, or other common supplements are generally safe with montelukast for many people, but individual responses vary. If you notice new symptoms after starting a supplement, report these changes to a healthcare professional.
If you are using an herbal product to manage allergies or asthma, consult with a healthcare professional about safety and interactions. Some products may interact with prescribed therapies or affect symptom control.
Do not start any new supplement regimen solely for the purpose of enhancing montelukast’s effect without professional guidance. A pharmacist can help assess potential interactions in your specific context.
Food generally does not have a major impact on montelukast absorption, but taking the tablet with a light meal can help some people tolerate the product better. Avoid heavy alcohol use if you notice drowsiness or mood changes coinciding with montelukast use, as alcohol can worsen some side effects for susceptible individuals.
Dietary choices that influence liver health or inflammation may indirectly affect how montelukast works over time. Maintain a balanced diet and discuss any significant dietary changes with your clinician, especially if you have chronic liver concerns or metabolic conditions.
In most cases, moderate alcohol consumption does not produce dangerous interactions with montelukast. However, every person is different. If you notice unusual symptoms after drinking alcohol while on montelukast, consult a clinician for tailored advice.
Inform any new healthcare provider about montelukast therapy before they prescribe new medicines, including antibiotics, antifungals, or other agents that are commonly used with respiratory diseases. A careful review helps reduce the risk of unintended interactions.
Montelukast may be prescribed during pregnancy if the potential benefits justify the risks. If you become pregnant while taking montelukast, inform your clinician. Do not stop therapy abruptly without professional advice, as uncontrolled allergy and asthma symptoms could also affect pregnancy outcomes.
Your clinician will weigh the importance of treatment against any potential risk to the developing baby and monitor you accordingly. If you are planning a pregnancy or are already pregnant, discuss montelukast use with your obstetrician or GP to ensure a safe plan is in place.
Where possible, pregnant patients should be monitored for any changes in symptoms and for the appearance of side effects that could affect both mother and baby. Shared decision‑making helps tailor therapy to individual circumstances.
As with all medicines taken during pregnancy, safety data in humans is considered alongside the severity of the underlying condition. If you have questions about alternatives or adjustments during pregnancy, seek professional guidance rather than relying on self‑care alone.
Breastfeeding while taking montelukast is a decision that should be discussed with a healthcare professional. Montelukast does pass into breast milk to some extent; the possible effects on a nursing infant should be weighed against the benefits of therapy for the mother.
The decision to use montelukast during breastfeeding should be made in consultation with a clinician. In many cases, the potential benefits to the mother may outweigh the uncertain risks to the infant. Your clinician can help determine the safest option for you and your baby.
If montelukast is continued while breastfeeding, doses are typically kept at the minimum effective level to reduce exposure to the infant. Monitor the infant for any unusual signs such as irritability, feeding difficulties, or sleep disturbances and report these to a clinician promptly.
Infants in the first weeks of life or those with underlying health concerns may require closer observation. Do not change your medication routine without medical advice, even if the infant appears well.
Always inform your healthcare team if you are breastfeeding or planning to start in the near future. They can help determine whether montelukast remains appropriate and whether any alternative treatments may be considered for the mother or infant.
Montelukast is often prescribed for children with asthma or allergic rhinitis. Dosing and formulation choices depend on age and weight. Your child’s clinician will provide age‑appropriate guidance and monitor response and safety.
Parents and caregivers should watch for mood or behaviour changes in children after starting montelukast, particularly in the early weeks. Any concerning changes warrant a prompt clinical review to determine whether montelukast remains suitable.
Regular follow‑ups help ensure symptom control and safety. If a child’s asthma control worsens or new side effects arise, the clinician may adjust the treatment plan or switch to another option.
In school‑age children, montelukast is sometimes offered as an option when inhaled therapies are impractical or not tolerated. The decision should be guided by a paediatrician or respiratory specialist and aligned with overall asthma management goals.
Older adults may respond differently to montelukast, and age‑related changes in drug metabolism can influence safety. Clinicians consider comorbidities and concurrent medicines when tailoring therapy for older patients.
If you are an older adult taking montelukast, inform any new healthcare provider about your full medication list, including non‑prescription products and supplements. This helps prevent potential interactions and ensures safe care continuity.
COMMON side effects do not typically differ by age, but a cautious approach is standard for the elderly. Report any unusual symptoms such as confusion, sleep disruption, or mood changes promptly for assessment.
As with any long‑term medication, regular reviews with a clinician support safe, evidence‑based use in older adults. If a management plan needs adjustment due to age‑related health changes, seek professional guidance promptly.
Singulair is taken orally, typically once daily, with or without food. Your clinician will specify the appropriate schedule and duration based on your condition and response. Do not adjust the dose or frequency without discussing with a healthcare professional.
Store montelukast tablets in a cool, dry place away from direct sunlight. Keep the medicine out of reach of children. Do not use tablets that appear damaged, discoloured, or have passed their expiry date. Return or dispose of unused medicines according to local guidelines.
Take montelukast consistently to maintain its protective effect, as irregular intake can reduce efficacy. If you forget a dose, check with a pharmacist or clinician for the recommended plan rather than doubling up doses.
If you are using montelukast alongside an inhaled therapy or nasal spray, continue those treatments as prescribed unless your clinician advises otherwise. Montelukast complements these therapies but does not replace them in most patients.
Contact your clinician if you develop an unexpected rash, swelling, fever, or significant mood changes. These could indicate a reaction or other health issue that requires medical assessment. If symptoms escalate rapidly or you have trouble breathing, seek urgent medical help.
Below are common concerns patients in the UK raise about montelukast. Answers are cautious and focused on safety, avoiding specific dosing details. If you have particular questions about your situation, consult your healthcare professional or the official patient information leaflet.
Introduction note: this section aims to address practical safety queries and how to respond to potential problems while using montelukast.
Can I start montelukast if I am currently using an inhaled steroid inhaler for asthma? Montelukast is often added to a broader asthma management plan. A clinician will determine if it’s appropriate for you and how it fits with your current therapies. Do not change your regimen without medical guidance.
Can montelukast be used with allergy injections (immunotherapy)? Interactions with allergy immunotherapy can vary. A clinician will review your whole treatment plan to ensure safety and compatibility and may adjust schedules accordingly.
Is it safe to drive or operate machinery while taking montelukast? For most people, montelukast does not cause drowsiness or impairment. If you notice sleepiness, dizziness, or confusion, discuss this with your clinician before driving or using heavy equipment.
What happens if I notice mood changes after starting montelukast? If mood changes, agitation, anxiety, or unusual behaviour occur, contact a clinician promptly. In rare cases, these symptoms may be serious and require urgent assessment.
Can montelukast affect blood tests or liver function tests? Routine blood tests are not required for everyone on montelukast, but your clinician may order tests if there are concerns or if you are taking other medicines that affect the liver. Report any signs of liver trouble such as unusual fatigue or jaundice.
Will I know if montelukast is not working for me? If your symptoms persist or worsen after starting montelukast, speak with your clinician. They may adjust the plan, add another therapy, or consider alternative options. Do not continue if you experience abnormal side effects or lack of symptom control without professional advice.
Are there common but harmless side effects I should not worry about? Mild headaches, stomach upset, or sleep disturbances are generally not unusual when starting montelukast. However, if these persist or affect daily life, seek guidance from a healthcare professional.
Should I avoid other asthma medicines when taking montelukast? Do not stop or change other asthma medications without discussing with a clinician. Your overall plan balances several therapies to achieve control with the safest approach for you.
Is montelukast suitable for children? Montelukast is used in children in certain circumstances, with dose and formulation tailored to age and weight. A paediatrician or respiratory specialist will guide this decision and monitor safety closely.
What should I do if I vomit after taking montelukast? If vomiting occurs soon after dosing, contact your clinician for advice. They may suggest re‑taking the dose or adjusting timing in a safe, evidence‑based way.
Can I stop montelukast suddenly if I feel better? Do not stop abruptly without consulting a clinician. Sudden cessation can lead to a rebound of symptoms or a shift in how the disease behaves. A gradual plan under professional guidance is preferred.
What if I need urgent medical help? If you experience severe swelling, trouble breathing, severe mood changes, or signs of an allergic reaction, seek urgent medical help immediately. Provide your healthcare team with details about montelukast use to aid assessment.
Your healthcare professional is the primary source of safe, personalised information about montelukast. The official patient information leaflet supplied with the medicine contains dosage, administration guidance, and safety warnings specific to the product you receive. In addition, reputable health organisations in the United Kingdom provide general information about asthma, allergy management, and pharmacovigilance.
If you prefer written materials, request a patient information leaflet from your pharmacist or clinician. These documents are designed to help you understand warnings, interactions, and what to do in common scenarios, such as missed doses or when symptoms persist.
For emergency or urgent concerns, contact local healthcare services or seek urgent medical help. If you are using montelukast and have concerns about safety, do not delay professional advice while seeking information online. Personalised guidance from a clinician remains essential to safe treatment decisions.
Always verify the source of information and ensure it reflects current UK practice and local regulations. The safety profile of montelukast is continually assessed by regulators and professional bodies, and updates may occur as new evidence emerges. Your clinician can explain any new recommendations in the context of your treatment plan.
14–21 days. Free from £151.46 .
5–9 days. £22.72
−10% when paying with cryptocurrency.
−10% on all repeat orders.
All orders are packed in neutral, unbranded boxes with no product name on the outside.
